Perpetual Ltd Has $1.36 Million Holdings in Bristol Myers Squibb Company $BMY

Perpetual Ltd boosted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 69.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,179 shares of the biopharmaceutical company’s stock after buying an additional 12,338 shares during the quarter. Perpetual Ltd’s holdings in Bristol Myers Squibb were worth $1,361,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BMY. Focus Financial Network Inc. boosted its stake in shares of Bristol Myers Squibb by 7.0% in the 3rd quarter. Focus Financial Network Inc. now owns 5,154 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 339 shares in the last quarter. KMG Fiduciary Partners LLC lifted its holdings in Bristol Myers Squibb by 2.9% during the 3rd quarter. KMG Fiduciary Partners LLC now owns 42,558 shares of the biopharmaceutical company’s stock valued at $1,919,000 after purchasing an additional 1,194 shares during the last quarter. Fiduciary Financial Group LLC boosted its position in Bristol Myers Squibb by 14.9% in the third quarter. Fiduciary Financial Group LLC now owns 8,262 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 1,071 shares in the last quarter. Independence Bank of Kentucky grew its stake in Bristol Myers Squibb by 14.5% during the third quarter. Independence Bank of Kentucky now owns 11,642 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 1,475 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC increased its holdings in shares of Bristol Myers Squibb by 10.8% during the third quarter. Baker Tilly Wealth Management LLC now owns 6,528 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 634 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $54.15 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The firm has a market cap of $110.24 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 8.29 and a beta of 0.29. The stock has a 50-day moving average price of $47.73 and a 200 day moving average price of $47.14.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. Bristol Myers Squibb’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.7%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers publicly announced an agreement with the U.S. government to improve affordability and access to medicines — a company release that frames the deal as preserving market access while responding to pricing pressures. This reduces regulatory uncertainty and the risk of punitive measures that could have hurt sales. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
• Positive Sentiment: BMY and partner BioNTech reported progress in immunotherapy clinical programs (first-line liver cancer and a kidney‑cancer trial update), which add long-term commercial optionality if late‑stage data confirms benefit. These pipeline moves support upside beyond near‑term pricing headwinds. New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
• Positive Sentiment: Analyst and media endorsements are visible: Guggenheim raised/maintained an elevated price target after an FDA priority review and media commentators (including Jim Cramer) are calling BMY a buy/value name — these signals can attract momentum and retail/institutional buyers. Guggenheim sets $62 target on Bristol-Myers Squibb Company (BMY) after FDA priority review
• Neutral Sentiment: Major press outlets report that nine pharma companies (including BMY) struck voluntary price agreements with the White House to link some U.S. prices to lower foreign prices and to avoid potential tariffs — this offers regulatory clarity but also implies longer‑term pricing pressure. Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
• Neutral Sentiment: Broader coverage (CNBC) confirms multiple large drugmakers are making similar deals with the administration — increases industry momentum toward pricing reforms but spreads the competitive/market impact across peers. Nine of the largest pharma companies ink deals with Trump to lower drug prices
• Neutral Sentiment: BMY set a Q4 2025 earnings release date (Feb. 5, 2026) — a near‑term catalyst investors will watch for sales impact from pricing agreements and pipeline progress. Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
• Negative Sentiment: Analyst model updates from Zacks Research trimmed several near‑term EPS estimates and cut FY2027 estimates modestly, implying some downward revision risk to earnings expectations if pricing concessions or volume shifts persist. (Zacks research notes summarized across recent releases.)
• Positive Sentiment: Market commentary pieces positioning BMY as a long‑term value stock may attract defensive/value investors given the company’s dividend/cash flow profile and pipeline depth. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wells Fargo & Company increased their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $54.62.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.